Racial differences in diffusion of intensity-modulated radiation therapy for localized prostate cancer - Abstract

Intensity-modulated radiation therapy (IMRT), an innovative treatment option for prostate cancer, has rapidly diffused over the past decade.

To inform our understanding of racial disparities in prostate cancer treatment and outcomes, this study compared diffusion of IMRT in African American (AA) and Caucasian American (CA) prostate cancer patients during the early years of IMRT diffusion using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database. A retrospective cohort of 947 AA and 10,028 CA patients diagnosed with localized prostate cancer from 2002 through 2006, who were treated with either IMRT or non-IMRT as primary treatment within 1 year of diagnoses was constructed. Logistic regression was used to examine potential differences in diffusion of IMRT in AA and CA patients, while adjusting for socioeconomic and clinical covariates. A significantly smaller proportion of AA compared with CA patients received IMRT for localized prostate cancer (45% vs. 53%, p < .0001). Racial differences were apparent in multivariable analysis though did not achieve statistical significance, as time and factors associated with race (socioeconomic, geographic, and tumor related factors) explained the preponderance of variance in use of IMRT. Further research examining improved access to innovative cancer treatment and technologies is essential to reducing racial disparities in cancer care.

Written by:
Cobran EK, Chen RC, Overman R, Meyer AM, Kuo TM, O'Brien J, Sturmer T, Sheets NC, Goldin GH, Penn DC, Godley PA, Carpenter WR.   Are you the author?
University of Georgia, College of Pharmacy, Athens, GA, USA; University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, NC, USA; UNC, Eshelman School of Pharmacy, Chapel Hill, NC, USA; UNC, Gillings School of Global Public Health, Chapel Hill, NC, USA; UNC, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.  

Reference: Am J Mens Health. 2015 Feb 5. pii: 1557988314568184.
doi: 10.1177/1557988314568184

PubMed Abstract
PMID: 25657192

UroToday.com Prostate Cancer Section